Johnson & Johnson (JNJ) operating KPIs
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$273.20−2.00 (-0.73%)
Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%
Johnson & Johnson abiomed (Impella heart pumps) sub-franchise — Worldwide operational (constant-currency) growth YoY (%) (%)
Form 8-K EX-99.2 Segment Sales Schedule
Latest, Q3 2026
-1.5%
Period ended Sep 30, 2026
Change on a year earlier
-17.1 pts
15.6% in Q3 2025
History
15 quarters
Since Q1 2023
Sources
15
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up abiomed (impella heart pumps) sub-franchise — worldwide operational (constant-currency) growth yoy (%)
Cite this data
StockData. (2026). Johnson & Johnson Abiomed (Impella heart pumps) sub-franchise — Worldwide operational (constant-currency) growth YoY (%) (%), quarterly Q1 2023–Q3 2026 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/mt_abiomed_ops_yoy
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.